Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Gyrate atrophy of choroid and retina

Orpha number ORPHA414
Synonym(s) HOGA
Hyperornithinemia
Hyperornithinemia - gyrate atrophy of choroid and retina
Ornithine aminotransferase deficiency
Prevalence Unknown
Inheritance
  • Autosomal recessive
Age of onset Childhood
ICD-10
  • E72.4
OMIM
UMLS
  • C0599035
MeSH
  • C537132
MedDRA -
SNOMED CT
  • 276426004
  • 33985005

Summary

Inherited hyperornithinemia is characterised by mitochondrial ornithine aminotransferase deficiency. Onset may occur in neonatal period with hyperammonemic coma; however, normal ammonemia levels are rapidly and definitely restored soon after. The main clinical manifestation of the disease is gyrate atrophy of the choroid and retina that begins during childhood with myopia and night blindness, followed by concentric shrinking of the visual field (tunnel vision) and a peculiar aspect of retinopathy on the funduscopy. The electroretinogram soon goes flat. Patients often develop subcapsular posterior cataract between the ages of 10 and 20 and become virtually blind between the ages of 40 and 50. Most have normal intelligence, although some may be moderately retarded and exhibit proximal muscular disorders. It is transmitted as an autosomal recessive trait. Mitochondrial ornithine aminotransferase is involved in the transamination of ornithine and alpha ketoglutarate into delta-I-pyroline-5-carboxylate and has vitamin B6 for a cofactor. Two genetic forms have been described: a pyridoxine responsive form and a pyridoxine unresponsive form. Diagnosis is made by demonstrating major plasmatic and urinary hyperornithinemia on the chromatography of aminoacids, and confirmed by measuring enzymatic activity in lymphocytes or cultured fibroblasts. Patients are all tested for pyridoxine sensitivity during 2 weeks by receiving 500 mg to 1g of pyridoxine daily. As a result, ornithine-sensitive patients demonstrate normal plasmatic and urinary ornithinemia and should receive lifelong ornithine supplements. Ornithine-resistant patients should follow a diet with limited protein intake and may be supplemented with proline, although its efficiency is still controversed.

Expert reviewer(s)

  • Pr Jean-Marie SAUDUBRAY

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.